Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch …

…, M Banzi, E Maartense, E Shmueli… - Journal of Clinical …, 2015 - ascopubs.org
Purpose The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin
in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free …

An interval> 7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease–free survival in patients with locally advanced …

H Tulchinsky, E Shmueli, A Figer, JM Klausner… - Annals of surgical …, 2008 - Springer
Background We assessed whether the time interval between neoadjuvant therapy and surgery
affects the operative and postoperative morbidity and mortality, the pathologic complete …

Long COVID in children: observations from a designated pediatric clinic

L Ashkenazi-Hoffnung, E Shmueli… - The Pediatric …, 2021 - journals.lww.com
Systematic data are lacking on pediatric long COVID. This study prospectively assessed 90
children with persistent symptoms who presented to a designated multidisciplinary clinic for …

The Role and Limitations of 18-Fluoro-2-deoxy-d-glucose Positron Emission Tomography (FDG-PET) Scan and Computerized Tomography (CT) in Restaging …

…, U Metser, R Geva, R Nakache, E Shmueli… - Journal of …, 2007 - Springer
Background Recent data confirmed the importance of 18-fluoro-2-deoxy-d-glucose positron
emission tomography (FDG-PET) in the selection of patients with colorectal hepatic …

High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation

E Shmueli, R Or, MY Shapira, IB Resnick… - The Journal of …, 2014 - academic.oup.com
We examined the rate, clinical impact, and risk factors of cytomegalovirus (CMV) drug
resistance in 561 patients who underwent 616 hematopoietic stem cell transplantations (HSCTs) …

[HTML][HTML] Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy–a single centre prospective study

ES Shmueli, A Itay, O Margalit, R Berger… - European journal of …, 2021 - Elsevier
… Author links open overlay panel Einat S. Shmueli a b 1 , Amit Itay a b 1 , Ofer Margalit a b ,
Raanan Berger a b , Sharon Halperin a , Menucha Jurkowicz a , Einav G. Levin b c , Itzchak …

[HTML][HTML] BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: a prospective cohort study

…, H Magen, T Hod, N Shem-Tov, ES Shmueli… - …, 2021 - thelancet.com
Background Trials of the Pfizer-BioNTech BNT162b2 mRNA vaccine showed 95% efficacy
in preventing symptomatic disease; however, the trials excluded immunocompromised …

Response to chemotherapy predicts survival following resection of hepatic colo‐rectal metastases in patients treated with neoadjuvant therapy

RM Small, N Lubezky, E Shmueli… - Journal of surgical …, 2009 - Wiley Online Library
Background Prognosis of patients following resection of CRC metastases to the liver has
traditionally been predicted by clinical risk factors. In the era of neoadjuvant chemotherapy, …

Treatment effects of elexacaftor/tezacaftor/ivacaftor in people with CF carrying non-F508del mutations

G Livnat, A Dagan, M Heching, E Shmueli, D Prais… - Journal of Cystic …, 2023 - Elsevier
Background In vitro studies have demonstrated rescue of CFTR function with Elexacaftor/Tezacaftor/Ivacaftor
(ETI) in several mutations other than F508del. However, clinical efficacy …

Risk factors for respiratory syncytial virus bronchiolitis hospitalizations in children with chronic diseases

E Shmueli, O Goldberg, M Mei‐Zahav… - Pediatric …, 2021 - Wiley Online Library
Risk factors for respiratory syncytial virus bronchiolitis hospitalizations in children with chronic
diseases - Shmueli - … Einat Shmueli and Ori Goldberg contributed equally to this work. …